BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15886741)

  • 1. Raloxifene for hormone replacement therapy (HRT).
    Adams D
    N Z Med J; 2005 May; 118(1214):U1451. PubMed ID: 15886741
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
    Bjarnason NH
    Dan Med Bull; 2005 May; 52(2):64-81. PubMed ID: 16009050
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women.
    da Costa LS; de Oliveira MA; Rubim VS; Wajngarten M; Aldrighi JM; Rosano GM; Neto CD; Gebara OC
    Am J Cardiol; 2004 Dec; 94(11):1453-6. PubMed ID: 15566926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can estrogen or selective estrogen-receptor modulators preserve cognitive function in elderly women?
    Mayeux R
    N Engl J Med; 2001 Apr; 344(16):1242-4. PubMed ID: 11309641
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women.
    Klein KP; Herrington DM
    Medscape Womens Health; 2002; 7(5):2. PubMed ID: 12466731
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.
    Sgarabotto M; Baldini M; Dei Cas A; Manotti C; Luciana Barilli A; Rinaldi M; Benassi L; Bacchi Modena A
    Thromb Res; 2007; 119(1):85-91. PubMed ID: 16499954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of estrogen and selective estrogen receptor modulators in anti-aging].
    Ohta H
    Clin Calcium; 2008 Jul; 18(7):986-94. PubMed ID: 18591752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
    Kastelan D; Korsić M
    Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter by Choi et al regarding article, "Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors".
    Choi BG; Vilahur G; Badimon JJ
    Circulation; 2009 Oct; 120(17):e147; author reply e148. PubMed ID: 19858421
    [No Abstract]   [Full Text] [Related]  

  • 10. Hormone alternative doesn't worsen vasomotor symptoms or impact urinary incontinence in post-menopausal women.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Mar; 15(5):7-9. PubMed ID: 15025087
    [No Abstract]   [Full Text] [Related]  

  • 11. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
    Med Lett Drugs Ther; 2006 May; 48(1234):37. PubMed ID: 16685245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of SERMs in postmenopausal women.
    Palmieri C; Lam EW; Vigushin D; Coombes RC
    Lancet; 2004 May; 363(9419):1477-8. PubMed ID: 15121421
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].
    Ohnaka K; Takayanagi R
    Clin Calcium; 2009 Aug; 19(8):1118-24. PubMed ID: 19638695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raloxifene, tamoxifen and vascular tone.
    Leung FP; Tsang SY; Wong CM; Yung LM; Chan YC; Leung HS; Yao X; Huang Y
    Clin Exp Pharmacol Physiol; 2007 Aug; 34(8):809-13. PubMed ID: 17600563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].
    Kozakiewicz K; Wycisk A
    Wiad Lek; 2006; 59(5-6):377-82. PubMed ID: 17017486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hormone replacement therapy and cardiovascular prevention. Where are we now?].
    Lerman J; Siseles N
    Medicina (B Aires); 2008; 68(3):251-7. PubMed ID: 18689159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone replacement Up-to-date. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis].
    Hosoi T
    Clin Calcium; 2007 Sep; 17(9):1419-23. PubMed ID: 17767033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
    Sambrook P
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors.
    Walsh BW
    Ann N Y Acad Sci; 2001 Dec; 949():163-7. PubMed ID: 11795349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.